Save Parkinson’s clinical research. Take part today
We’re calling on the Parkinson’s community to take part in 5 important clinical studies that are currently at risk of closure.
Celebrating neuroscience in spring 2023
We are partnering with the British Neuroscience Association (BNA) to plan and deliver the BNA International Festival of Neuroscience 2023. Drawing together leading neuroscientists, including Parkinson’s researchers, from across the globe to celebrate and share the latest thinking in neuroscience today.
NRG Therapeutics awarded £2.68m to develop treatments that could slow Parkinson's
Biotech company, NRG Therapeutics, has today announced an Innovate UK award to continue its drug development project, supported by the Parkinson's Virtual Biotech, into life-changing new treatments.
Researchers find brain scans linked to the severity of Parkinson’s symptoms
Research led by Cambridge University and part funded by Parkinson’s UK shows that a form of brain scan could help identify those at risk of specific Parkinson’s symptoms. The results could pave the way to better treatment of Parkinson’s.
Clinical trial of world’s smallest deep brain stimulation device hits headlines
A trial of a new miniaturised deep brain stimulation (DBS) device, being carried out at Southmead Hospital in Bristol, aims to make improvements to existing surgery.
Progress made in partnership between pharma and people with Parkinson's
A pioneering partnership between global biopharmaceutical company UCB, Parkinson’s UK and the Parkinson's Foundation in the US is laying the foundations for people with Parkinson's to feed into the drug development pipeline.
Pioneering clinical trial opens new sites
The TOP HAT clinical trial for visual hallucinations in Parkinson's and Lewy body dementia has recently opened 4 new trial sites.
Investigating an app to improve non-motor symptom management
An app for people with Parkinson’s to remotely monitor and manage their non-motor symptoms is now entering the testing phase.
Nanobodies that target LRRK2 could have potential for Parkinson's
Treatments targeting a protein called LRRK2 are currently being tested in clinical trials for Parkinson's. Researchers hope they may have the ability to slow the progression of the condition which is something no current treatment can do.